Filing Flows › Neogenomics (NEO) › Q2 2026 › vs Q1 2026
Neogenomics (NEO) Q2 2026 vs Q1 2026 (quarter over quarter)
Neogenomics's revenue rose $15.0M (+8%) from $187M in Q1 2026 to $202M in Q2 2026. The biggest changes: Client direct billing +$6.3M (+5%); Commercial insurance +$5.3M (+17%); Medicare and other government +$3.3M (+14%).
Neogenomics, Q2 2026: revenue $202M (+11% year over year), operating margin -4.8%, net earnings $2.2M, operating cash flow $20.0M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 5.8% | -7.0% | +12.9 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Client direct billing | $138M | $132M | $6.3M | +5% |
| Commercial insurance | $36.3M | $30.9M | $5.3M | +17% |
| Medicare and other government | $27.4M | $24.1M | $3.3M | +14% |
| Revenue | $202M | $187M | $15.0M | +8% |
| Other income, net | $11.6M | $663K | $10.9M | 17× |
| Income tax benefit | $412K | $472K | −$60K | -13% |
| Costs & expenses | $214M | $205M | $8.8M | +4% |
| Operating costs | $211M | $205M | $6.5M | +3% |
| Net earnings | $2.2M | −$17.1M | $19.3M | — |
| Cost of revenue | $110M | $106M | $4.0M | +4% |
| Research & development | $10.8M | $9.5M | $1.2M | +13% |
| Sales & marketing | $27.3M | $23.8M | $3.4M | +14% |
| General & admin | $63.6M | $65.7M | −$2.1M | -3% |
| Operating cash sources | $26.7M | $8.9M | $17.7M | +198% |
| Depreciation & amortization | $16.2M | $16.4M | −$203K | -1% |
| Share-based compensation | $8.2M | $9.6M | −$1.4M | -15% |
| Working capital & other | $6.7M | $17.1M | −$10.4M | -61% |
| Operating cash flow | $20.0M | −$8.1M | $28.1M | — |
| Free cash flow (OCF − capex) | $11.7M | −$13.1M | $24.9M | — |
| Capital expenditures | $8.2M | $5.0M | $3.2M | +64% |
Questions
How much did Neogenomics's revenue grow quarter over quarter in Q2 2026?
Neogenomics's revenue rose $15.0M (+8%) from $187M in Q1 2026 to $202M in Q2 2026.
What drove Neogenomics's revenue change in Q2 2026?
Client direct billing +$6.3M (+5%); Commercial insurance +$5.3M (+17%); Medicare and other government +$3.3M (+14%).